000			03194nam a22003493i 4500
001			EBC30607168
003			MiAaPQ
005			20240122002120.0
006			m o d |
007			cr cnu||||||||
008			231124s2023 xx o ||||0 eng d
020			_a9789240074569 _q(electronic bk.)
035			_a(MiAaPQ)EBC30607168
035			_a(Au-PeEL)EBL30607168
035			_a(OCoLC)1402186796
040			_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ
245	1	0	_aTarget Product Profiles for Animal Plasma-Derived Antivenoms : _bAntivenoms for Treatment of Snakebite Envenoming in Sub-Saharan Africa.
250			_a1st ed.
264		1	_aGeneva : _bWorld Health Organization, _c2023.
264		4	_c�2023.
300			_a1 online resource (45 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
505	0		_aCover -- Title -- Copyright -- Contents -- Acknowledgements -- Glossary of key terms and abbreviations -- Executive summary -- Introduction -- Unmet medical need/problem -- Rationale -- Use-case scenarios -- Scope of TPPs -- Indications and contraindications -- Manufacturing considerations -- Active pharmaceutical ingredient -- Finished product form -- Protein and immunoglobulin content -- Preclinical efficacy studies -- Clinical considerations -- Frequency and route of administration -- Stability, storage, presentation and packaging -- Affordability and access -- Supportive/adjunctive therapy -- Training and education -- Animal plasma-derived antivenom TPP list -- Target product profiles for sub-Saharan Africa -- Common characteristics of TPPs -- All sub-Saharan African, animal plasma-derived antivenoms -- Scope -- Manufacturing Consideraton -- Performance -- Operational Characteristics -- Specific characteristics of TPPs -- Broad-spectrum pan-African polyvalent antivenoms -- Scope -- Manufacturing Considerations -- Performance -- Sub-Saharan African monovalent antivenoms -- Scope -- Manufacturing Considerations -- Performance -- Pan-African polyvalent antivenoms for neurotoxic envenoming -- Scope -- Manufacturing Considerations -- Performance -- Pan-African polyvalent antivenoms for non-neurotoxic envenoming -- Scope -- Manufaturing Considerations -- Performance -- Clinical effectiveness of antivenoms for sub‑Saharan Africa -- Clinical Outcomes -- Death -- Restoration of blood coagulability -- Neurotoxicity -- Amputation and other functional loss -- Tissue necrosis -- Rhabdomyolysis -- Cost-effectiveness of antivenoms for sub-Saharan Africa -- References -- Bibliography.
588			_aDescription based on publisher supplied metadata and other sources.
590			_aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
655		4	_aElectronic books.
776	0	8	_iPrint version: _a _tTarget Product Profiles for Animal Plasma-Derived Antivenoms _dGeneva : World Health Organization,c2023
797	2		_aProQuest (Firm)
856	4	0	_uhttps://ebookcentral.proquest.com/lib/bacm-ebooks/detail.action?docID=30607168 _zClick to View
999			_c316364 _d316364